TALENs: a widely applicable technology for targeted genome editing
- PMID: 23169466
- PMCID: PMC3547402
- DOI: 10.1038/nrm3486
TALENs: a widely applicable technology for targeted genome editing
Abstract
Engineered nucleases enable the targeted alteration of nearly any gene in a wide range of cell types and organisms. The newly-developed transcription activator-like effector nucleases (TALENs) comprise a nonspecific DNA-cleaving nuclease fused to a DNA-binding domain that can be easily engineered so that TALENs can target essentially any sequence. The capability to quickly and efficiently alter genes using TALENs promises to have profound impacts on biological research and to yield potential therapeutic strategies for genetic diseases.
Conflict of interest statement
J.K.J. has a financial interest in Transposagen Biopharmaceuticals. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Figures
Similar articles
-
A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity.Nucleic Acids Res. 2011 Nov;39(21):9283-93. doi: 10.1093/nar/gkr597. Epub 2011 Aug 3. Nucleic Acids Res. 2011. PMID: 21813459 Free PMC article.
-
Origins of Programmable Nucleases for Genome Engineering.J Mol Biol. 2016 Feb 27;428(5 Pt B):963-89. doi: 10.1016/j.jmb.2015.10.014. Epub 2015 Oct 23. J Mol Biol. 2016. PMID: 26506267 Free PMC article. Review.
-
The application of transcription activator-like effector nucleases for genome editing in C. elegans.Methods. 2014 Aug 1;68(3):389-96. doi: 10.1016/j.ymeth.2014.04.013. Epub 2014 Apr 26. Methods. 2014. PMID: 24780522
-
Off-target effects of engineered nucleases.FEBS J. 2016 Sep;283(17):3239-48. doi: 10.1111/febs.13760. Epub 2016 Jun 6. FEBS J. 2016. PMID: 27208701 Review.
-
Engineering designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-Fast assembly.Curr Protoc Mol Biol. 2012 Oct;Chapter 12:Unit 12.15. doi: 10.1002/0471142727.mb1215s100. Curr Protoc Mol Biol. 2012. PMID: 23026907 Free PMC article.
Cited by
-
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy.J Adv Res. 2022 Sep;40:135-152. doi: 10.1016/j.jare.2021.11.018. Epub 2021 Dec 4. J Adv Res. 2022. PMID: 36100322 Free PMC article. Review.
-
Application of CRISPR/Cas9 in Crop Quality Improvement.Int J Mol Sci. 2021 Apr 19;22(8):4206. doi: 10.3390/ijms22084206. Int J Mol Sci. 2021. PMID: 33921600 Free PMC article. Review.
-
Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids.Integr Biol (Camb). 2016 Jun 13;8(6):672-83. doi: 10.1039/c6ib00039h. Epub 2016 May 9. Integr Biol (Camb). 2016. PMID: 27156572 Free PMC article. Review.
-
Integration of drug, protein, and gene delivery systems with regenerative medicine.Drug Deliv Transl Res. 2015 Apr;5(2):168-86. doi: 10.1007/s13346-013-0165-8. Drug Deliv Transl Res. 2015. PMID: 25787742 Free PMC article. Review.
-
Mutations in zebrafish pitx2 model congenital malformations in Axenfeld-Rieger syndrome but do not disrupt left-right placement of visceral organs.Dev Biol. 2016 Aug 1;416(1):69-81. doi: 10.1016/j.ydbio.2016.06.010. Epub 2016 Jun 11. Dev Biol. 2016. PMID: 27297886 Free PMC article.
References
-
- Baker M. Gene-editing nucleases. Nat Methods. 2012;9:23–26. - PubMed
-
- Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636–646. - PubMed
-
- Boch J, Bonas U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu Rev Phytopathol. 2010;48:419–436. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials